Korean Circulation Journal

  • 제53권9호
  • /
  • Pages.621-631
  • /
  • 2023
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Efficiency of MVP ECG Risk Score for Prediction of Long-Term Atrial Fibrillation in Patients With ICD for Heart Failure With Reduced Ejection Fraction

  • Levent Pay (Department of Cardiac, Ardahan State Hospital) ;
  • Ahmet Cagdas Yumurtas (Department of Cardiology, Dr Siyami Ersek Thoracic and Cardiovascular Surgery Training Hospital) ;
  • Ozan Tezen (Department of Cardiology, Dr Siyami Ersek Thoracic and Cardiovascular Surgery Training Hospital) ;
  • Tugba Cetin (Department of Cardiology, Dr Siyami Ersek Thoracic and Cardiovascular Surgery Training Hospital) ;
  • Semih Eren (Department of Cardiology, Dr Siyami Ersek Thoracic and Cardiovascular Surgery Training Hospital) ;
  • Goksel Cinier (Department of Cardiac Electrophysiology, Basaksehir Cam ve Sakura City Hospital) ;
  • Mert Ilker Hayiroglu (Department of Cardiology, Dr Siyami Ersek Thoracic and Cardiovascular Surgery Training Hospital) ;
  • Ahmet Ilker Tekkesin (Department of Cardiac Electrophysiology, Basaksehir Cam ve Sakura City Hospital)
  • 투고 : 2022.12.22
  • 심사 : 2023.05.09
  • 발행 : 2023.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background and Objectives: The morphology-voltage-P-wave duration (MVP) electrocardiography (ECG) risk score is a newly defined scoring system that has recently been used for atrial fibrillation (AF) prediction. The aim of this study was to evaluate the ability of the MVP ECG risk score to predict AF in patients with an implantable cardioverter defibrillator (ICD) and heart failure with reduced ejection fraction in long-term follow-up. Methods: The study used a single-center, and retrospective design. The study included 328 patients who underwent ICD implantation in our hospital between January 2010 and April 2021, diagnosed with heart failure. The patients were divided into low, intermediate and high-risk categories according to the MVP ECG risk scores. The long-term development of atrial fibrillation was compared among these 3 groups. Results: The low-risk group included 191 patients, the intermediate-risk group 114 patients, and the high-risk group 23 patients. The long-term AF development rate was 12.0% in the low-risk group, 21.9% in the intermediate risk group, and 78.3% in the high-risk group. Patients in the high-risk group were found to have 5.2 times higher rates of long-term AF occurrence compared to low-risk group. Conclusions: The MVP ECG risk score, which is an inexpensive, simple and easily accessible tool, was found to be a significant predictor of the development of AF in the long-term follow-up of patients with an ICD with heart failure with reduced ejection fraction. This risk score may be used to identify patients who require close follow-up for development and management of AF.

키워드

참고문헌

  1. Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980;303:322-4.
  2. Proietti R, Labos C, Davis M, et al. A systematic review and meta-analysis of the association between implantable cardioverter-defibrillator shocks and long-term mortality. Can J Cardiol 2015;31:270-7.
  3. Mittal S, Movsowitz C, Steinberg JS. Ambulatory external electrocardiographic monitoring: focus on atrial fibrillation. J Am Coll Cardiol 2011;58:1741-9.
  4. Mendieta G, Guasch E, Weir D, et al. Advanced interatrial block: a predictor of covert atrial fibrillation in embolic stroke of undetermined source. J Electrocardiol 2020;58:113-8.
  5. Martinez-Selles M, Elosua R, Ibarrola M, et al. Advanced interatrial block and P-wave duration are associated with atrial fibrillation and stroke in older adults with heart disease: the BAYES registry. Europace 2020;22:1001-8.
  6. Alexander B, Haseeb S, van Rooy H, et al. Reduced P-wave voltage in lead I is associated with development of atrial fibrillation in patients with coronary artery disease. J Atr Fibrillation 2017;10:1657.
  7. Alexander B, Milden J, Hazim B, et al. New electrocardiographic score for the prediction of atrial fibrillation: the MVP ECG risk score (morphology-voltage-P-wave duration). Ann Noninvasive Electrocardiol 2019;24:e12669.
  8. McManus DD, Hsu G, Sung SH, et al. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J Am Heart Assoc 2013;2:e005694.
  9. Sakhuja R, Shah AJ, Keebler M, Thakur RK. Atrial fibrillation in patients with implantable defibrillators. Cardiol Clin 2009;27:151-61.
  10. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-726.
  11. Kizilirmak F, Demir GG, Gokdeniz T, et al. Changes in electrocardiographic P wave parameters after cryoballoon ablation and their association with atrial fibrillation recurrence. Ann Noninvasive Electrocardiol 2016;21:580-7.
  12. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373-498.
  13. Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease - double trouble. Adv Med Sci 2018;63:30-5.
  14. Mogensen UM, Jhund PS, Abraham WT, et al. Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 2017;70:2490-500.
  15. Pistoia F, Sacco S, Tiseo C, Degan D, Ornello R, Carolei A. The Epidemiology of atrial fibrillation and stroke. Cardiol Clin 2016;34:255-68.
  16. Wang A, Green JB, Halperin JL, Piccini JP Sr. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol 2019;74:1107-15.
  17. Verdecchia P, Angeli F, Reboldi G. Hypertension and atrial fibrillation: doubts and certainties from basic and clinical studies. Circ Res 2018;122:352-68.
  18. Blomstrom-Lundqvist C, Traykov V, Erba PA, et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Europace 2020;22:515-49.
  19. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417-27.
  20. Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008;51:1357-65.
  21. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008;359:1009-17.
  22. Klein RC, Raitt MH, Wilkoff BL, et al. Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Cardiovasc Electrophysiol 2003;14:940-8. 
  23. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-5.
  24. Bunch TJ, Day JD, Olshansky B, Stolen KQ, Mullin CM; INTRINSIC RV Study Investigators. Newly detected atrial fibrillation in patients with an implantable cardioverter-defibrillator is a strong risk marker of increased mortality. Heart Rhythm 2009;6:2-8.